Cargando…

The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes

BACKGROUND AND OBJECTIVES: The primary aim was to determine risk factors for flumazenil administration during postanesthesia recovery. A secondary aim was to describe outcomes among patients who received flumazenil. METHODS: Patients admitted to the postanesthesia recovery room at a large, academic,...

Descripción completa

Detalles Bibliográficos
Autores principales: Seelhammer, Troy G., DeGraff, Eric M., Behrens, Travis J., Robinson, Justin C., Selleck, Kristen L., Schroeder, Darrell R., Sprung, Juraj, Weingarten, Toby N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391726/
https://www.ncbi.nlm.nih.gov/pubmed/29631877
http://dx.doi.org/10.1016/j.bjane.2017.12.008
_version_ 1784770913039810560
author Seelhammer, Troy G.
DeGraff, Eric M.
Behrens, Travis J.
Robinson, Justin C.
Selleck, Kristen L.
Schroeder, Darrell R.
Sprung, Juraj
Weingarten, Toby N.
author_facet Seelhammer, Troy G.
DeGraff, Eric M.
Behrens, Travis J.
Robinson, Justin C.
Selleck, Kristen L.
Schroeder, Darrell R.
Sprung, Juraj
Weingarten, Toby N.
author_sort Seelhammer, Troy G.
collection PubMed
description BACKGROUND AND OBJECTIVES: The primary aim was to determine risk factors for flumazenil administration during postanesthesia recovery. A secondary aim was to describe outcomes among patients who received flumazenil. METHODS: Patients admitted to the postanesthesia recovery room at a large, academic, tertiary care facility after surgery under general anesthesia from January 1, 2010, to April 30, 2015, were identified and matched to 2 controls each, by age, sex, and surgical procedure. Flumazenil was administered in the recovery phase immediately after general anesthesia, according to the clinical judgment of the anesthesiologist. Demographic, procedural, and outcome data were extracted from the electronic health record. Conditional logistic regression, accounting for the 1:2 matched-set case-control study designs, was used to assess characteristics associated with flumazenil use. RESULTS: The incidence of flumazenil administration in the postanesthesia care unit was 9.9 per 10,000 (95% CI, 8.4–11.6) general anesthetics. History of obstructive sleep apnea (Odds Ratio [OR] = 2.27; 95% CI 1.02–5.09), longer anesthesia (OR = 1.13; 95% CI 1.03–1.24 per 30 minutes), use of total intravenous anesthesia (OR = 6.09; 95% CI 2.60–14.25), and use of benzodiazepines (OR = 8.17; 95% CI 3.71–17.99) were associated with risk for flumazenil administration. Among patients who received midazolam, cases treated with flumazenil received a higher median (interquartile range) dose than controls: 3.5 mg (2.0–4.0 mg) vs. 2.0 mg (2.0–2.0 mg), respectively (p < 0.001). Flumazenil use was correlated with a higher rate of unanticipated noninvasive positive pressure ventilation, longer postanesthesia care unit stay, and increased rate of intensive care unit admissions. CONCLUSIONS: Patients who required flumazenil postoperatively had received a higher dosage of benzodiazepines and utilized more postoperative health care resources. More conservative perioperative use of benzodiazepines may improve postoperative recovery and use of health care resources.
format Online
Article
Text
id pubmed-9391726
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93917262022-08-21 The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes Seelhammer, Troy G. DeGraff, Eric M. Behrens, Travis J. Robinson, Justin C. Selleck, Kristen L. Schroeder, Darrell R. Sprung, Juraj Weingarten, Toby N. Braz J Anesthesiol Scientific Article BACKGROUND AND OBJECTIVES: The primary aim was to determine risk factors for flumazenil administration during postanesthesia recovery. A secondary aim was to describe outcomes among patients who received flumazenil. METHODS: Patients admitted to the postanesthesia recovery room at a large, academic, tertiary care facility after surgery under general anesthesia from January 1, 2010, to April 30, 2015, were identified and matched to 2 controls each, by age, sex, and surgical procedure. Flumazenil was administered in the recovery phase immediately after general anesthesia, according to the clinical judgment of the anesthesiologist. Demographic, procedural, and outcome data were extracted from the electronic health record. Conditional logistic regression, accounting for the 1:2 matched-set case-control study designs, was used to assess characteristics associated with flumazenil use. RESULTS: The incidence of flumazenil administration in the postanesthesia care unit was 9.9 per 10,000 (95% CI, 8.4–11.6) general anesthetics. History of obstructive sleep apnea (Odds Ratio [OR] = 2.27; 95% CI 1.02–5.09), longer anesthesia (OR = 1.13; 95% CI 1.03–1.24 per 30 minutes), use of total intravenous anesthesia (OR = 6.09; 95% CI 2.60–14.25), and use of benzodiazepines (OR = 8.17; 95% CI 3.71–17.99) were associated with risk for flumazenil administration. Among patients who received midazolam, cases treated with flumazenil received a higher median (interquartile range) dose than controls: 3.5 mg (2.0–4.0 mg) vs. 2.0 mg (2.0–2.0 mg), respectively (p < 0.001). Flumazenil use was correlated with a higher rate of unanticipated noninvasive positive pressure ventilation, longer postanesthesia care unit stay, and increased rate of intensive care unit admissions. CONCLUSIONS: Patients who required flumazenil postoperatively had received a higher dosage of benzodiazepines and utilized more postoperative health care resources. More conservative perioperative use of benzodiazepines may improve postoperative recovery and use of health care resources. Elsevier 2018-02-04 /pmc/articles/PMC9391726/ /pubmed/29631877 http://dx.doi.org/10.1016/j.bjane.2017.12.008 Text en © 2018 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Seelhammer, Troy G.
DeGraff, Eric M.
Behrens, Travis J.
Robinson, Justin C.
Selleck, Kristen L.
Schroeder, Darrell R.
Sprung, Juraj
Weingarten, Toby N.
The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes
title The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes
title_full The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes
title_fullStr The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes
title_full_unstemmed The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes
title_short The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes
title_sort use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391726/
https://www.ncbi.nlm.nih.gov/pubmed/29631877
http://dx.doi.org/10.1016/j.bjane.2017.12.008
work_keys_str_mv AT seelhammertroyg theuseofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT degraffericm theuseofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT behrenstravisj theuseofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT robinsonjustinc theuseofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT selleckkristenl theuseofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT schroederdarrellr theuseofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT sprungjuraj theuseofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT weingartentobyn theuseofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT seelhammertroyg useofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT degraffericm useofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT behrenstravisj useofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT robinsonjustinc useofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT selleckkristenl useofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT schroederdarrellr useofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT sprungjuraj useofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes
AT weingartentobyn useofflumazenilforbenzodiazepineassociatedrespiratorydepressioninpostanesthesiarecoveryrisksandoutcomes